Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 7, 2025; 31(29): 109947
Published online Aug 7, 2025. doi: 10.3748/wjg.v31.i29.109947
Published online Aug 7, 2025. doi: 10.3748/wjg.v31.i29.109947
Targeted therapy combined with immunotherapy vs trifluridine/tipiracil with bevacizumab as late-line therapy in metastatic colorectal cancer
Zhao Gao, Xiao-Yun Wang, Shi-Kai Wu, Xuan Jin, Department of Medical Oncology, Peking University First Hospital, Beijing 100034, China
Xiao-Yan Wang, Tao Song, Zhi-Gang Shen, Department of Pharmacy, Jilin Cancer Hospital, Changchun 130012, Jilin Province, China
Author contributions: Gao Z wrote the manuscript; Jin X and Wu SK conceived of the review and edited the manuscript; Gao Z and Wang XY collected and analyzed the data; Shen ZG, Song T, Wang XY and Wu SK analyzed the data; Gao Z, Wang XY, Song T, Shen ZG, Wang XY, Wu SK, Jin X read and approved the final manuscript.
Supported by the National High Level Hospital Clinical Research Funding (Multi-Center Clinical Research Project of Peking University First Hospital), No. 2022CR65.
Institutional review board statement: This study has been approved by the Ethics Committee of Peking University First Hospital (approval No. 2025R0190-0001) and Jilin Cancer Hospital (approval No. 202501-003-01).
Informed consent statement: Consent to participate not required.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Data sharing statement: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xuan Jin, PhD, Department of Medical Oncology, Peking University First Hospital, No. 8 Xishiku Street, Beijing 100034, China. jinxuanbdyy@outlook.com
Received: May 26, 2025
Revised: June 9, 2025
Accepted: July 11, 2025
Published online: August 7, 2025
Processing time: 71 Days and 9.4 Hours
Revised: June 9, 2025
Accepted: July 11, 2025
Published online: August 7, 2025
Processing time: 71 Days and 9.4 Hours
Core Tip
Core Tip: Targeted therapy combined with anti-programmed cell death 1 immunotherapy (TP) and trifluridine/tipiracil combined with bevacizumab (TB) are two common therapies for patients with late-line therapy in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). However, it is still unclear which therapy can bring better prognosis. This study aims to evaluate the effectiveness and safety of TP vs TB as the late-line regimen for MSS mCRC in the real world.